Literature DB >> 27413150

Serotonin and Antidepressant SSRIs Inhibit Rat Neuroendocrine Dopamine Neurons: Parallel Actions in the Lactotrophic Axis.

David J Lyons1, Rachida Ammari2, Arash Hellysaz2, Christian Broberger3.   

Abstract

UNLABELLED: Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression, but sexual side effects often compromise compliance. These reproductive dysfunctions are likely mediated by elevations of the hormone prolactin. Yet, how serotonin (5-HT) and SSRIs cause changes in prolactin secretion is not known. Here, using in vitro whole-cell patch-clamp recordings, we show that 5-HT hyperpolarizes and abolishes phasic discharge in rat neuroendocrine tuberoinfundibular dopamine (TIDA) neurons, the main inhibitor of prolactin secretion. This process is underpinned by 5-HT1A receptor-mediated activation of G-protein-coupled inwardly rectifying K(+)-like currents. We further demonstrate that the SSRIs, fluoxetine and sertraline, directly suppress TIDA neuron activity through parallel effects, independent of 5-HT transmission. This inhibition involves decreased intrinsic excitability and a slowing of TIDA network rhythms. These findings indicate that SSRIs may inhibit neuroendocrine dopamine release through both 5-HT-dependent and -independent actions, providing a mechanistic explanation for, and potential molecular targets for the amelioration of, the hyperprolactinemia and sexual dysfunction associated with these drugs. SIGNIFICANCE STATEMENT: Depression affects approximately one-tenth of the population and is commonly treated with selective serotonin reuptake inhibitors (SSRIs; e.g., Prozac). Yet, many patients withdraw from SSRI therapy due to sexual side effects (e.g., infertility, menstrual disturbances, and impotence). Although it is generally accepted that sexual side effects are due to the ability of these drugs to elevate blood levels of the hormone prolactin, the mechanism for this hormonal imbalance is not known. Here, we show that SSRIs can inhibit hypothalamic dopamine neurons that normally suppress the secretion of prolactin. Intriguingly this inhibition can be explained both by increased serotonin activity and also by parallel serotonin-independent actions.
Copyright © 2016 the authors 0270-6474/16/367392-15$15.00/0.

Entities:  

Keywords:  depression; dopamine; fluoxetine; neuroendocrine; prolactin; tuberoinfundibular

Mesh:

Substances:

Year:  2016        PMID: 27413150      PMCID: PMC6705542          DOI: 10.1523/JNEUROSCI.4061-15.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  5 in total

Review 1.  Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?

Authors:  Silvia Giatti; Silvia Diviccaro; Giancarlo Panzica; Roberto Cosimo Melcangi
Journal:  Endocrine       Date:  2018-04-19       Impact factor: 3.633

2.  Hypocretin/Orexin Peptides Excite Rat Neuroendocrine Dopamine Neurons through Orexin 2 Receptor-Mediated Activation of a Mixed Cation Current.

Authors:  David J Lyons; Arash Hellysaz; Rachida Ammari; Christian Broberger
Journal:  Sci Rep       Date:  2017-02-01       Impact factor: 4.379

3.  Transient effects of multi-infusion ketamine augmentation on treatment-resistant depressive symptoms in patients with treatment-resistant bipolar depression - An open-label three-week pilot study.

Authors:  Chuanjun Zhuo; Feng Ji; Hongjun Tian; Lina Wang; Feng Jia; Deguo Jiang; Ce Chen; Chunhua Zhou; Xiaodong Lin; Jingjing Zhu
Journal:  Brain Behav       Date:  2020-07-03       Impact factor: 2.708

Review 4.  The Prolactin Family of Hormones as Regulators of Maternal Mood and Behavior.

Authors:  Teodora Georgescu; Judith M Swart; David R Grattan; Rosemary S E Brown
Journal:  Front Glob Womens Health       Date:  2021-12-01

5.  Multiple-scale neuroendocrine signals connect brain and pituitary hormone rhythms.

Authors:  Nicola Romanò; Anne Guillou; David J Hodson; Agnès O Martin; Patrice Mollard
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.